| Name | Title | Contact Details |
|---|
Eastern Isotopes is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Galileo Life, our goal is nothing short of a revolution in the way that healthcare is talked about and delivered. Through the establishment of a dedicated and professional network of Galileo Smart Clinics throughout the country, our vision is the development of a national-level holistic health services and wellness platform specializing in assessment, diagnostic, home-monitoring, and treatment services. The Healthcare Renaissance is here, and Galileo Life Sciences intends to herald the change in Healthcare and re-imagine Healthcare options. Galileo Life Sciences is about the pursuit of alternative solutions both in addition to, and outside of the current Western medical healthcare paradigm. We believe in taking the best of the conventional and combining it with what nature has provided - and what droves of scientific research continues to uncover and confirm - to help us heal, relieve pain, improve sleep, alleviate anxiety, increase appetite, offset the side effects of powerful pharmacological and medical treatments, and much more. Galileo Life Sciences extends an invitation to all practitioners and entrepreneurs in the Healthcare sector, to join us and become part of the bold and rapid global movement to ensure that healthcare is accessible by all in the world.
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, chemical and biopharmaceutical industries that have in-house genomic capabilities. Dyadic will also collaborate with companies whose genomic capabilities are limited, discovering and expressing biological materials for these strategic partners. In addition, Dyadic, using these proprietary systems, will continue to commercialize enzymes for use in targeted markets, including the animal nutrition, detergent, ethanol, pulp and paper, biopharmaceutical, starch and textile industries. Dyadic expects to generate revenue from its product sales, revenue generated from research and development services and funding as well as revenue generated from licensing and other strategic collaborations in the form of milestone and royalty payments.
M2GEN is an oncology-focused bioinformatics solutions company advancing precision medicine and transforming cancer care through clinical and molecular data and analytics tools. The company`s innovative dataset accelerates the discovery, development, and delivery of personalized therapies. M2GEN`s Oncology Research Information Exchange Network® (ORIEN), an alliance of NCI-Designated cancer centers that gather de-identified and lifetime-consented clinical and genomic patient data for research purposes, enables a collaborative approach to the fight against cancer for patients today and tomorrow. M2GEN currently has more than 300,000 total consented patients across a network of 18 cancer centers in 10 states.
Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator. Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with the global biopharmaceutical companies by providing a financing solution to them as sponsors of clinical trials, which are conducted by patient care providers (PCPs) such as hospitals, medical research institutes, centers, and clinics.